Guggenheim raises Helus Pharma stock price target on trial data
Guggenheim raised its price target on MSG Rangers stock to $299 from $278 on Tuesday, maintaining a Buy rating. The company's stock is currently trading at $247.84, having surged 7.7% over the past week and nearing its 52-week high of $255. Guggenheim's updated model was based on the company's fiscal 2027 first-quarter earnings.
Despite not hosting an earnings call due to the timing of the quarter, Guggenheim believes the Rangers have a significant discount between its net asset value and intrinsic value. Valuations from Sportico and Forbes were cited at $3.65 billion and $4.0 billion, respectively, while the Rangers' market cap is just $2.99 billion. The stock trades near its 52-week high with an EXCELLENT financial health score, and BTIG has adjusted its price target to $313, citing a valuation gap and increased investor interest following the Rangers' spin-off from Madison Square Garden Knickerbockers.
Written by urgent.news from Investing.com's reporting — not their text. Machine-written — may contain errors; check the original before relying on it.
This story
This is one outlet's version. Read the fullest account.